Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||BLU-701 + Osimertinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BLU-701||BLU701|BLU 701||EGFR Inhibitor 4th gen 3||BLU-701 is a reversible EGFR inhibitor that blocks the activity of mutant forms of EGFR, including C797S, while sparing wild-type EGFR, which results in reduced downstream signaling and potentially leads to decreased tumor growth (Cancer Res 2021;81(13_Suppl):Abstract nr 1262).|
|Osimertinib||Tagrisso||AZD9291||EGFR Inhibitor 3rd gen 23||Tagrisso (osimertinib) is a third-generation EGFR inhibitor that selectively binds mutant forms of the EGF receptor, inhibiting downstream signaling and potentially reducing cell proliferation and growth in EGFR overexpressing tumors (PMID: 29151359). Tagrisso (osimertinib) is FDA-approved for use as adjuvant therapy after resection in patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletion or L858R, as first-line therapy in patients with metastatic NSCLC harboring EGFR exon 19 deletion or L858R, and for treatment in patients with metastatic NSCLC harboring EGFR T790M whose disease progressed after EGFR TKI therapy (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05153408||Phase Ib/II||BLU-701 BLU-701 + Osimertinib BLU-701 + Carboplatin + Pemetrexed Disodium||(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC||Recruiting||USA||0|